Libro blanco de las ACES Pediátricas 2024

Libro Blanco de las ACES Pediátricas 2024 316 ❚ European Training Programme in Paediatric Haematology and Oncology    _________________________________________________________________________________________ SIOP Europe – March 2020 Module 1: Learning Points  Cancer epidemiology  Genetic and environmental factors predisposing for malignancies  Clinical presentation of tumors, potential metastatic sites and tumor staging  Emergencies at diagnosis and during treatment, including spinal cord compression,  intracranial hypertension, tumor lysis syndrome, abdominal occlusion, septic shock,  mediastinal acute compressive syndrome, and arterial hypertension  Imaging, including functional Fluorodeoxyglucose Positron Emission Tomography (FDG‐ PET) in lymphoma and in other selected tumors; functional MRI in brain and other solid  tumors; MIBG scintigraphy in neuroblastoma, and other new radiological procedures that  may be important for the assessment of response and treatment strategies  Principles of chemotherapy, immunotherapy and new agents: pharmacokinetics,  pharmacodynamics, mechanisms of drug resistance, side effects and both short‐ and long‐ term complications related to chemotherapy or new therapies  Spectrum of molecular biology of paediatric cancer   Interactions between chemotherapy, immunotherapy and concomitantly administered  drugs    Treatment for haematological malignancies and solid tumors according to current  national/international protocols at diagnosis and relapse   Supportive care, including infection management, pain control and blood products  transfusion   Principles of bone marrow and peripheral stem cell transplantation and other cellular  therapies   Role of radiotherapy in different tumours  Role of surgery in different tumours    Principles of tissue collection for diagnosis and biological studies  Prognostic factors and therapeutic implications   Molecular markers as diagnostic and prognostic tools with treatment implications,  including concepts of intra‐tumoral heterogeneity and clonal evolution   Basic concepts of evidence‐based medicine and clinical trial methodology – early and late  phase   Ethical issues, consent, data protection   Basic concepts of ‘Survivorship” and late effects